Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Actinogen Medical ( (AU:ACW) ) has issued an update.
Actinogen Medical announced the presentation of an academic poster at the Alzheimer’s Association International Conference in Toronto, showcasing the clinical validation of Xanamem’s activity in the brain. The poster highlights the positive clinical effects of Xanamem in lowering CNS cortisol in patients with major depressive disorder, supporting its potential as a treatment for brain diseases like Alzheimer’s and depression. The company also participated in the conference with a sponsored booth, providing an opportunity to engage with healthcare professionals and discuss their late-stage clinical program and advancements in dementia research.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential applications in Fragile X Syndrome and other conditions. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and neuropsychological burdens associated with these diseases.
Average Trading Volume: 7,728,998
Technical Sentiment Signal: Sell
Current Market Cap: A$81.02M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.